share_log

Novo Integrated Sciences | 10-Q: Q3 2024 Earnings Report

Novo Integrated Sciences | 10-Q: Q3 2024 Earnings Report

Novo Integrated Sciences | 10-Q:2024财年三季报
美股SEC公告 ·  07/20 05:11

Moomoo AI 已提取核心信息

Novo Integrated Sciences reported financial results for the quarter ended May 31, 2024, with revenues of $3,151,851, a slight decrease from $3,292,933 in the same period last year. The company's operating loss widened to $2,520,203 from $1,430,418 year-on-year, primarily due to increased operating expenses and a significant loss from the change in fair value of derivative liability. Net loss for the quarter was substantial at $13,741,903, compared to $1,497,330 in the previous year, largely impacted by the derivative liability and foreign currency exchange losses. For the nine-month period, revenues increased by 10% to $10,213,661, but the net loss also grew to $21,168,374 from $10,054,098. The company's financial performance was affected by various factors, including changes in product costs, higher operating costs, and increased interest expenses due to...Show More
Novo Integrated Sciences reported financial results for the quarter ended May 31, 2024, with revenues of $3,151,851, a slight decrease from $3,292,933 in the same period last year. The company's operating loss widened to $2,520,203 from $1,430,418 year-on-year, primarily due to increased operating expenses and a significant loss from the change in fair value of derivative liability. Net loss for the quarter was substantial at $13,741,903, compared to $1,497,330 in the previous year, largely impacted by the derivative liability and foreign currency exchange losses. For the nine-month period, revenues increased by 10% to $10,213,661, but the net loss also grew to $21,168,374 from $10,054,098. The company's financial performance was affected by various factors, including changes in product costs, higher operating costs, and increased interest expenses due to a higher average principal balance of convertible notes. Novo Integrated Sciences also highlighted business developments such as the launch of MiTelemed+, the expansion of its healthcare services, and the development of health and wellness products. Looking ahead, the company plans to continue focusing on its three primary pillars: service networks, interconnected technology, and health and wellness products, to drive future growth.
Novo综合科学报告了2024年5月31日截止季度的财务业绩,营收为315万美元,略微下降,与去年同期329.3万美元相比。由于营业费用和衍生负债公允价值变动的巨额亏损影响,公司的营业亏损由去年的143万美元增至252万零203美元。季度净亏损高达1374万零1903美元,大幅下降,去年同期为149.7万美元,主要是由于衍生负债和外汇兑换损失所致。九个月期间,营收增长了10%,达到1,021.4万美元,但净亏损也从去年的1,005.4万美元增至2,116.8万美元。公司的财务表现受到各种因素的影响,包括产品成本变化、更高的营业成本以及由于可转换票据平均本金余额的增加而导致的利息支出增加。Novo综合科学还强调了业务发展的诸多方面,如推出MiTelemed+,扩展其医疗服务,以及开发健康与保健产品。展望未来,公司计划继续专注于其三大支柱:服务网络、互联科技和健康与保健产品,以推动未来的增长。
Novo综合科学报告了2024年5月31日截止季度的财务业绩,营收为315万美元,略微下降,与去年同期329.3万美元相比。由于营业费用和衍生负债公允价值变动的巨额亏损影响,公司的营业亏损由去年的143万美元增至252万零203美元。季度净亏损高达1374万零1903美元,大幅下降,去年同期为149.7万美元,主要是由于衍生负债和外汇兑换损失所致。九个月期间,营收增长了10%,达到1,021.4万美元,但净亏损也从去年的1,005.4万美元增至2,116.8万美元。公司的财务表现受到各种因素的影响,包括产品成本变化、更高的营业成本以及由于可转换票据平均本金余额的增加而导致的利息支出增加。Novo综合科学还强调了业务发展的诸多方面,如推出MiTelemed+,扩展其医疗服务,以及开发健康与保健产品。展望未来,公司计划继续专注于其三大支柱:服务网络、互联科技和健康与保健产品,以推动未来的增长。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息